Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | F10 | P00742 | 4/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917881 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3LTB4RLTB4R2 | |
| SCHEMBL16060526 | 0.91 | DRD2 (0.47) | DRD2DRD4DRD3F2F10 | |
| SCHEMBL20272323 | 0.91 | DRD2 (0.47) | DRD2DRD4DRD3F2F10 | |
| SCHEMBL16061961 | 0.89 | DRD2 (0.48) | DRD2DRD4DRD3F2F10 | |
| SCHEMBL5917872 | 0.83 | F2 (0.55) | F2F10ITGB3PRSS1PRSS2 | |
| SCHEMBL5918015 | 0.83 | F2 (0.55) | F2F10ITGB3PRSS1PRSS2 | |
| SCHEMBL5917903 | 0.81 | FFAR1 (0.47) | DRD2DRD4DRD3POLBHPGD | |
| SCHEMBL30640313 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPK1HTTALOX5 | |
| SCHEMBL30640308 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPK1HTTALOX5 | |
| SCHEMBL6800337 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPK1HTTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1764456-A | Treatment of related diseases using full alpha-7 nACh receptor agonists | PHARMACIA & UPJOHN CO LLC (US) | 2006-04-26 | — | — | CN | disclosed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | disclosed |
| EP-1587511-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | Pharmacia & Upjohn Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951868-B2 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | TPMT, PAICS, MALT1 | DRD2 3702/4885DRD4 3525/4885DRD3 4126/4885 |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | DRD2 3412/4885DRD4 3995/4885DRD3 3326/4885 |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | CHRNA7, CHRNA1, CHRNG | DRD2 2278/4885DRD4 2982/4885DRD3 2824/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | DRD2 74/4885DRD4 88/4885DRD3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.